New Concepts in Vaccines for Mucosal Non-Enteric Human Bacterial Pathogens
Since the introduction of vaccination in the seventeenth century, the prevention of infectious disease by immunologic methods has been a widely pursued goal of medical practitioners. Until the mid-twentieth century vaccines consisted primarily of inactivated intact organisms or extracts of intact organisms. In 1962, over 100 such vaccine products were available for use in the United States. Many of these products were associated with significant local and systemic toxicity and relatively few could claim efficacy in appropriately designed clinical trials. With a reassessment in the federal drug regulatory mandates after the thalidomide disaster in the 1960’s, many products with no proven value were removed from the market. Along with the changes occurring in control of product distribution, work in understanding the pathogenesis of human infection, the nature of the microbial surface, and the scope of the human immune response led to changes in vaccine products which reflected the search for safe and efficacious vaccine products. Over the past decade with application of improved chemical and chromatographic methods combined with the introduction of molecular genetics technology, a wide variety of new vaccines is becoming available.
KeywordsHaemophilus Influenzae Outer Membrane Protein Neisseria Gonorrhoeae Capsular Polysaccharide Neisseria Meningitidis
Unable to display preview. Download preview PDF.
- 2.Apicella MA: Neisseria meningitidis, in The Practices and Principles of Infectious Diseases, edited by; Mandell, G. L. , Douglass, R. G. , and Bennett, J. E. , John wiley and Sons, Inc., New York, NY 1978 and 1983.Google Scholar
- 8.Campagnari AA, Gupta MR, Dudas KC, Murphy TF and Apicella MA. Development of a lipooligosaccharide based serotyping system for Haemophilus influenzae. Infect. Immun. 54:843–847, 1987.Google Scholar
- 20.Wandan MH, Rizh F, El-Akkad AM, et al: A controlled field trial of a serogroup A meningococcal polysaccharide vaccine. Bull WHO, 48:667–673, 1973.Google Scholar
- 22.Eskola J, Kayhty H, Gordon LK, Hovi T, Stenvik M, Ronnberg PR, Kela E, Peltola H. Simultaneous administration of Haemophilus influenzae type b capsular polysaccharidediphtheria toxoid conjugate vaccine with routine diphtheriatetanus-pertussis and inactivated poliovirus vaccinations of childhood. Pediatr. Infect. Dis. J. 7:480–4, 1988.PubMedCrossRefGoogle Scholar
- 28.Brinton C. In: Immunobiology of Neisseria gonorrhoeae. ASM publications, 1978. Washington, DC, pp. 155–178.Google Scholar
- 33.David DW, West EP, McKenna W, Thompson SA and Sparling PF. A pleiotropic iron-uptake mutant of Neisseria meningitidis lacks a 70-kilodalton iron-regulated protein. Infect. Immun. 56 : 977–983, 1988.Google Scholar
- 36.Murphy TF, Bartos LC, Campagnari AA, Nelson MB and Apicella MA. Antigenic characterization of the P6 protein of nontypable Haemophilus influenzae. Infect. Immun. 54 : 751–760, 1986.Google Scholar